TrialCancer science2008

Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: prognostic factors and unique toxicity profile.

Yutaka Hattori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.